Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605874 | 0.88 | CYP4F2 (0.42) | KDM4E | |
| SCHEMBL3615358 | 0.87 | SMN1; SMN2 (0.49) | SLC22A12FFAR1FFAR4PPARGKDM4E | |
| SCHEMBL3606995 | 0.84 | LIPG (0.39) | PPARG | |
| SCHEMBL3605106 | 0.83 | GPBAR1 (0.36) | KDM4EMAPT | |
| SCHEMBL3618268 | 0.82 | GPBAR1 (0.41) | FFAR1PPARGKDM4EMAPTPTGDR2 | |
| SCHEMBL3610953 | 0.81 | CYP4F2 (0.37) | KDM4EMAPT | |
| SCHEMBL3605188 | 0.79 | CA2 (0.43) | SLC22A12FFAR1KDM4EMAPTPTGDR2 | |
| SCHEMBL3599881 | 0.78 | GPBAR1 (0.40) | KDM4EMAPTPTGDR2 | |
| SCHEMBL3614548 | 0.78 | GPBAR1 (0.32) | KDM4EMAPT | |
| SCHEMBL3604684 | 0.76 | HSD17B10 (0.38) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006243-B2 | HIV inhibiting 6-substituted pyrimidines | JANSSEN R&D IRELAND (IE) | 2015-04-14 | — | — | US | disclosed |
| US-20100016396-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016317-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-01-21 | — | — | US | disclosed |
| EP-2128138-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-2114901-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | Tibotec Pharmaceuticals (IE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008080964-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | SLC5A1, SLC5A2, GLP1R | SLC22A12 608/4885FFAR1 735/4885FFAR4 653/4885 |
| US-20100016317-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | CCR5, CTR9, NR1H3 | SLC22A12 4068/4885FFAR1 2619/4885FFAR4 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.